Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]Credit Agreement • February 27th, 2018 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • February 27th, 2018 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of February 5, 2018, is by and among ANI PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders (as hereinafter defined) party hereto, and CITIZENS BANK, N.A., a national banking association, as administrative agent for the Lenders under the Credit Agreement (as hereinafter defined) (in such capacity, the “Administrative Agent”). Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement.
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] ASSET...Asset Purchase Agreement • February 27th, 2018 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT (this “Agreement”) is made and executed as of December 29, 2017, by and among AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Södertälje, Sweden and with offices at SE-431 83 Mölndal, Sweden (“Sweden Seller”), AstraZeneca UK Limited, a company incorporated in England under no. 03674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, England CB2 0AA (“UK Seller”), and ANI Pharmaceuticals, Inc., a Delaware corporation (“Buyer”).
